144 related articles for article (PubMed ID: 35304097)
1. Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.
Bühler K; Roeder C; Schwarze JE; Lispi M; Allignol A; Falla E; Lukyanov V; D Hooghe T; Fischer R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):188-202. PubMed ID: 35304097
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.
Bühler KF; Fischer R; Verpillat P; Allignol A; Guedes S; Boutmy E; Bilger W; Richter E; D'Hooghe T
Reprod Biol Endocrinol; 2021 Jun; 19(1):90. PubMed ID: 34134695
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands.
Fragoulakis V; Pescott CP; Smeenk JM; van Santbrink EJ; Oosterhuis GJ; Broekmans FJ; Maniadakis N
Appl Health Econ Health Policy; 2016 Dec; 14(6):719-727. PubMed ID: 27581117
[TBL] [Abstract][Full Text] [Related]
4. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
[TBL] [Abstract][Full Text] [Related]
5. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
Souza PMG; Carvalho BR; Nakagawa HM; Rassi TRE; Barbosa ACP; Silva AA
JBRA Assist Reprod; 2017 Jun; 21(2):67-69. PubMed ID: 28609269
[TBL] [Abstract][Full Text] [Related]
6. A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection.
Esteves SC; Schertz JC; Verza S; Schneider DT; Zabaglia SF
Reprod Biol Endocrinol; 2009 Oct; 7():111. PubMed ID: 19828024
[TBL] [Abstract][Full Text] [Related]
7. The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.
Yang C; Dong N; Li F; Ji Y; Pan Y; She H
J Ovarian Res; 2022 Jun; 15(1):74. PubMed ID: 35729654
[TBL] [Abstract][Full Text] [Related]
8. A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chen MJ; Yi YC; Guu HF; Chen YF; Kung HF; Chang JC; Chuan ST; Chen LY
Front Endocrinol (Lausanne); 2022; 13():931756. PubMed ID: 36046790
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).
Grynberg M; Cedrin-Durnerin I; Raguideau F; Herquelot E; Luciani L; Porte F; Verpillat P; Helwig C; Schwarze JE; Paillet S; Castello-Bridoux C; D'Hooghe T; Benchaïb M
Best Pract Res Clin Obstet Gynaecol; 2023 Jun; 88():102308. PubMed ID: 36707343
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
11. Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.
Schwarze JE; Venetis C; Iniesta S; Falla E; Lukyanov V; de Agustin Calvo E; D Hooghe T; Roeder C; Matorras R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):203-216. PubMed ID: 35227619
[TBL] [Abstract][Full Text] [Related]
12. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
13. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
14. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis.
Barriere P; Porcu-Buisson G; Hamamah S
Appl Health Econ Health Policy; 2018 Feb; 16(1):65-77. PubMed ID: 29124676
[TBL] [Abstract][Full Text] [Related]
16. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review.
Trew GH; Brown AP; Gillard S; Blackmore S; Clewlow C; O'Donohoe P; Wasiak R
Reprod Biol Endocrinol; 2010 Nov; 8():137. PubMed ID: 21059191
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Best Pract Res Clin Obstet Gynaecol; 2023 Jul; 89():102350. PubMed ID: 37320996
[TBL] [Abstract][Full Text] [Related]
19. The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome.
Kan O; Simsir C; Atabekoglu CS; Sonmezer M
Gynecol Endocrinol; 2019 Oct; 35(10):869-872. PubMed ID: 30973022
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
Bergh C; Howles CM; Borg K; Hamberger L; Josefsson B; Nilsson L; Wikland M
Hum Reprod; 1997 Oct; 12(10):2133-9. PubMed ID: 9402268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
